News & Updates

Based on observational studies, patients with axial spondyloarthritis (axSpA) treated with biologics are at higher risk of inflammatory bowel disease (IBD), while findings from randomized controlled trials (RCTs) suggest that treatment with etanercept (ETN) tends to increase such risk compared to other antitumour necrosis factor (anti-TNF) therapies, according to the result of a meta-analysis.

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.

Dual antiplatelet therapy (DAPT) using cilostazol appears to be more beneficial than single antiplatelet therapy, with the results of a study suggesting that DAPT helps lower the incidence of ischemic stroke recurrence without increasing the risk of severe or life-threatening bleeding.

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.